The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center Journal Article


Authors: Favaretto, R. L.; Shariat, S. F.; Chade, D. C.; Godoy, G.; Adamy, A.; Kaag, M.; Bochner, B. H.; Coleman, J.; Dalbagni, G.
Article Title: The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center
Abstract: Background: The prognostic impact of primary tumor location on outcomes for patients with upper-tract urothelial carcinoma (UTUC) is still contentious. Objective: To test the association between tumor location and disease recurrence and cancer-specific survival (CSS) in patients treated with radical nephroureterectomy (RNU) for UTUC. Design, setting, and participants: Prospectively collected data were retrospectively reviewed from 324 consecutive patients treated with RNU between 1995 and 2008 at a single tertiary referral center. Patients who had previous radical cystectomy, preoperative chemotherapy, previous contralateral UTUC, or metastatic disease at presentation were excluded. This left 253 patients for analysis. Tumor location was categorized as renal pelvis or ureter based on the location of the dominant tumor. Recurrences in the bladder only, in nonbladder sites, and in any site were analyzed. Intervention: All patients were treated with RNU. Measurements: Recurrence-free survival and CSS probabilities were estimated using Kaplan-Meier and Cox regression analyses. Results and limitations: Median follow-up for survivors was 48 mo. The 5-yr recurrence-free probability (including bladder recurrence) and CSS estimates were 32% and 78%, respectively. On multivariable analysis, pathologic stage was the only predictor for disease recurrence (p = 0.01). Tumor location was not an independent predictor for recurrence (hazard ratio: 1.19; p = 0.3), and there was no difference in the probability of disease recurrence between ureteral and renal pelvic tumors (p = 0.18). On survival analysis, we also found no differences between ureteral and renal pelvic tumors on probability of CSS (p = 0.2). On multivariate analysis, pathologic stage (p < 0.0001) and nodal status (p = 0.01) were associated with worse CSS. This study is limited by its retrospective nature. Conclusions: Our study did not show any differences in recurrence and CSS rates between patients with ureteral and renal pelvic tumors treated with RNU. © 2010 European Association of Urology.
Keywords: survival; adult; cancer survival; aged; middle aged; cancer surgery; survival rate; retrospective studies; major clinical study; cancer recurrence; disease free survival; tumor localization; neoplasm recurrence, local; recurrence; retrospective study; urogenital tract cancer; kidney neoplasms; nephrectomy; urothelial carcinoma; nephroureterectomy; ureteral neoplasms; ureter; carcinoma, transitional cell; kidney pelvis; ureter tumor; bladder; renal pelvis; kidney pelvis tumor
Journal Title: European Urology
Volume: 58
Issue: 4
ISSN: 0302-2838
Publisher: Elsevier Science, Inc.  
Date Published: 2010-10-01
Start Page: 574
End Page: 580
Language: English
DOI: 10.1016/j.eururo.2010.07.003
PUBMED: 20637540
PROVIDER: scopus
PMCID: PMC4174409
DOI/URL:
Notes: --- - "Export Date: 20 April 2011" - "CODEN: EUURA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jonathan Coleman
    341 Coleman
  2. Guido Dalbagni
    325 Dalbagni
  3. Matthew G Kaag
    32 Kaag
  4. Daher Chade
    19 Chade
  5. Shahrokh Shariat
    68 Shariat
  6. Bernard Bochner
    468 Bochner
  7. Guilherme Godoy
    23 Godoy